Certain rare gene mutations, previously ignored, appear to contribute substantially to the development of lupus, new research found, pointing to the potential for targeted therapies for the condition. The study, “Functional rare and low frequency variants in BLK and BANK1 contribute to human lupus,” was published in …
In studying how mycophenolate mofetil treatment affects immune cells and blood markers in people with systemic lupus erythematosus (SLE), researchers uncovered an immune pathway that may explain why is lupus suppressed by this medication. Their findings might…
Platelet-bound C4d (PC4d), one of Exagen‘s patented biomarkers, may be used along with other available biomarkers to estimate the risk of thrombosis — the formation of blood clots — among people with systemic lupus erythematosus (SLE), a study shows. The study, “Platelet-bound C4d, low C3…
Tofacitinib tablets, a medicine approved to treat rheumatoid and psoriatic arthritis, may work for lessening signs and symptoms of arthritis and skin rash in people with systemic lupus erythematosus (SLE), a…
Michigan Medicine researchers were granted up to $10.2 million by the Autoimmunity Centers of Excellence (ACE) to develop new projects seeking treatments for autoimmune diseases including lupus. In particular, the team from the University of Michigan’s academic medical center is focused on exploring the relationship between molecular targets…
In observance of World Lupus Day and Lupus Awareness Month, Aurinia Pharmaceuticals has announced disease awareness and educational initiatives aimed at supporting patients with lupus nephritis, a serious complication of systemic lupus erythematosus (SLE). World Lupus Day was May 10, and Lupus Awareness Month is marked…
A comprehensive report co-led by pharmaceutical company GSK underscores the need to enhance care for those living with lupus, and to raise awareness about the disease. The release of the report, titled “A Vision for Lupus,” was timed to World Lupus Day on May 10. Coordinated by…
A survey found that 63 percent of American respondents either had never heard of the autoimmune disease lupus, or knew little about it, the Lupus Foundation of America (LFA) announced during Lupus Awareness Month in May. Results of the Lupus Awareness Study call for better understanding of…
At the 2019 annual meeting of the Childhood Arthritis and Rheumatology Research Alliance (CARRA), leaders from the Lupus Foundation of America (LFA) joined other experts in offering insights into critical needs in childhood lupus. Held in Louisville, Ky. in April, the event focused on the latest advances…
Mallinckrodt Pharmaceuticals has completed enrollment for its Phase 4 clinical trial evaluating the safety and effectiveness of H.P. Acthar Gel (repository corticotropin injection) in patients with persistently active systemic lupus erythematosus (SLE). The company expects the first results to be available by early 2020. “I am delighted that enrollment is completed, and look forward…